Revvity stock (US76155R1086): FDA assay clearance, outlook to 2026 and fresh collaboration momentum

Revvity has updated its multi?year outlook, reported new quarterly numbers, secured FDA clearance for a testosterone assay and advanced a collaboration around its Revvity Signals platform — developments that keep the diagnostics and life?science tools group in focus for US investors.

Revvity has remained on the radar of healthcare and life?science tools investors after a cluster of recent news: the company reported first?quarter 2026 revenue of about 711 million USD, raised its full?year 2026 revenue outlook to a range of roughly 2.81 to 2.84 billion USD, and announced that its Immunodiagnostic Systems unit received US FDA clearance for a Total Testosterone automated chemiluminescence immunoassay, according to Simply Wall St summarizing company disclosures as of 05/10/2026Simply Wall St as of 05/10/2026.

Despite the combination of higher guidance and regulatory progress, commentary noted that the stock traded lower by roughly 5% in the immediate aftermath of these updates, underlining a cautious market mood toward life?science tools names even when fundamentals improve, according to the same analysis of the share reactionSimply Wall St as of 05/10/2026.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Revvity Inc.
• Sector/industry: Life?science tools and diagnostics
• Headquarters/country: Waltham, United States
• Core markets: Clinical diagnostics labs, pharmaceutical and biotech research customers, academic and government research institutions
• Key revenue drivers: Diagnostics assays and instruments, life?science research tools, and informatics platforms
• Home exchange/listing venue: New York Stock Exchange (ticker: RVTY)
• Trading currency: US dollar (USD)

Revvity Inc.: core business model

Revvity emerged as a focused life?science and diagnostics group following portfolio reshaping and a rebranding from PerkinElmer’s prior configuration, positioning itself between specialized diagnostics suppliers and broader healthcare technology players. The company develops and supplies reagents, instruments and software that enable customers to detect diseases, analyze biological samples and support drug discovery workflows across a range of therapeutic areas.

On the diagnostics side, Revvity’s offerings include assays, analyzers and related consumables used in clinical laboratories for areas such as prenatal screening, newborn screening, infectious disease testing and endocrine as well as reproductive health assessments. The newly cleared Total Testosterone immunoassay fits into this framework by broadening the test menu available on an automated system and allowing labs to run more endocrine?related diagnostics on a single platform, according to the recent FDA clearance overview described in market commentarySimply Wall St as of 05/10/2026.

In parallel, Revvity operates a life?science tools and analytical solutions segment that serves pharmaceutical and biotechnology companies, contract research organizations and academic labs. This business provides technologies for high?throughput screening, genomics and proteomics workflows, cellular imaging and other research applications that underpin drug development and translational medicine. The company’s software and informatics capabilities, including the Revvity Signals platform, are designed to help customers manage and interpret complex data generated in these scientific environments.

Revvity’s business model therefore blends recurring revenue from consumables and reagents with instrument sales and software licenses. For investors, this mix can create a blend of defensiveness and cyclicality: recurring test and reagent usage can be tied to underlying diagnostic testing volumes, while equipment and software cycles can be more sensitive to capital spending trends at pharma and academic customers. The recent guidance update to a 2026 revenue range around the low? to mid?2.8?billion?USD mark suggests management is targeting steady expansion from current levels as the portfolio matures, according to the same outlook summarySimply Wall St as of 05/10/2026.

Main revenue and product drivers for Revvity Inc.

Diagnostics platforms represent a central pillar of Revvity’s revenue base. The company’s Immunodiagnostic Systems unit, for instance, focuses on chemiluminescence immunoassay platforms and associated test menus. FDA clearance for the Total Testosterone automated assay is notable in this context because it allows clinical labs to add an important endocrine and reproductive health parameter to an existing analyzer rather than investing in a separate system, potentially supporting both instrument placements and higher recurring reagent pull?through over time, according to recent coverage of the clearance and menu expansionSimply Wall St as of 05/10/2026.

Beyond individual assays, Revvity’s broader diagnostics portfolio spans areas such as prenatal and neonatal testing, infectious diseases and metabolic disorders. These markets can be influenced by public health programs and reimbursement regimes, which may introduce regional variability but also tend to support sustained test volumes where screening is embedded in standard of care. As healthcare systems in the United States and other regions continue to emphasize early detection and precision medicine, the company’s diagnostic franchises aim to align with demand for more accurate and efficient testing workflows, a theme highlighted in sector?oriented commentary focused on the potential expansion of diagnostics suppliers within major equity benchmarksKalkine Media as of 04/15/2026.

On the life?science tools side, Revvity’s revenue drivers include laboratory instruments and consumables used in drug discovery, high?content screening, genomics, and bioanalytical workflows. These offerings can be sensitive to R&D budgets at pharmaceutical and biotech firms as well as funding conditions for academic and government research. When capital spending is healthy, instrument demand can support growth; when budgets tighten, customers may delay equipment upgrades while still purchasing critical reagents and consumables. Investors in the US healthcare tools space therefore often monitor macro indicators like biotech funding trends and large?pharma pipeline activity when assessing revenue visibility for companies such as Revvity.

A newer and strategically important revenue driver is informatics and data analytics, centered on the Revvity Signals platform. Recent market coverage highlighted a collaboration between Revvity and Eli Lilly that aims to expand access to predictive models via Revvity Signals, essentially combining the company’s data infrastructure with pharmaceutical expertise to support research decisions, according to a report summarizing the partnership’s market impactAd-hoc-news as of 05/17/2026.

This collaboration news coincided with a session in which Revvity shares gained nearly 5% to close around 109 USD, suggesting that investors viewed the tie?up as an incremental positive for the company’s informatics and pharma?facing strategy, according to the same market summary referencing Intellectia’s coverage of the stock reactionAd-hoc-news as of 05/17/2026. For US investors, such collaborations can signal an effort to position Revvity not just as a hardware and reagents supplier but also as a partner in digital and AI?enabled research ecosystems.

Why Revvity Inc. matters for US investors

Revvity is listed on the New York Stock Exchange under the ticker RVTY and therefore directly accessible for US retail investors who follow the healthcare and life?science tools segment. The company operates at the intersection of diagnostics, research tools and data platforms, which means its performance can reflect broader themes such as adoption of advanced lab automation, growth in genetic and molecular testing, and the digital transformation of R&D across the biopharma industry.

According to price?history data, Revvity shares have shown only modest appreciation over the past year, with a low single?digit percentage gain over 12 months and a slightly negative year?to?date return, underscoring that the market remains selective toward life?science tools names, as indicated by chart information on a US market data portalMarketBeat as of 05/17/2026. For US investors, this combination of moderate share performance, ongoing cost?structure work and portfolio optimization may frame Revvity as a potential recovery or execution story within a still?volatile subsector.

Sector?focused commentary has pointed out that expanded diagnostics offerings across major equity indices like the S&P 500 could provide leverage to trends such as aging populations, chronic disease monitoring and preventive screening, themes in which Revvity participates through its lab?based testing systems and reproductive health platformsKalkine Media as of 04/15/2026. Against this backdrop, the company’s raised 2026 revenue outlook and incremental regulatory wins may be watched closely by market participants assessing whether the business can translate scientific and commercial initiatives into sustained top?line and earnings growth.

Conclusion

Revvity currently sits at an interesting juncture: the company has reported solid first?quarter 2026 revenue around 711 million USD, raised its full?year 2026 sales outlook into a range near 2.81 to 2.84 billion USD, and secured FDA clearance for a new Total Testosterone assay that broadens its endocrine and reproductive health testing capabilities, according to recent coverage of the results and regulatory progressSimply Wall St as of 05/10/2026. At the same time, collaboration news around the Revvity Signals platform and Eli Lilly has highlighted the company’s ambitions in data?driven research workflows, drawing a positive short?term share?price response in one recent sessionAd-hoc-news as of 05/17/2026. For US investors, the balance of execution on growth initiatives, external demand conditions for diagnostics and research tools, and the market’s appetite for healthcare technology names will likely remain key factors in how the stock is valued over the coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.